ArticleAtherosclerosis2025
Antisense oligonucleotide inhibition of HMGB1 attenuates angiotensin II-induced abdominal aortic aneurysms.
Article in Atherosclerosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification and Validation of Plasma Protein Biomarkers for Abdominal Aortic Aneurysm Using Integrated Proteomics.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
aimsVascular inflammation is a hallmark of abdominal aortic aneurysms (AAA) but the mechanism of these effects is undefined. High-mobility group box 1 (HMGB1) has potent inflammatory properties and has been implicated in various vascular diseases. We determined a role for HMGB1 in AAA pathogenesis utilizing an antisense oligonucleotide (ASO) to inhibit synthesis of the protein. METHODS AND
resultsTo identify molecular signatures and biological pathways associated with AAA, we analyzed RNA sequencing (RNA-seq) data from patients with AAA (GSE57691) and mice with angiotensin II (AngII)-induced AAA (GSE17901) obtained from the GEO database. Transcriptomic analysis revealed a marked upregulation of HMGB1 in both human and mouse aneurysmal tissue. AngII infusion into male LDLR-/- mice significantly increased HMGB1 protein abundance in the abdominal aorta after 7 days consistent with a role in AAA initiation. To assess the functional role of HMGB1 in AAA formation protein synthesis was inhibited using an ASO. Hypercholesterolemia was induced in male mice by expressing PCSK9-D377Y and maintained on a Western diet before being infused with AngII (1000 ng/kg/min) for 4 weeks to induce AAA. Mice (n = 15 per group) received subcutaneous injections of either phosphate-buffered saline or HMGB1 ASO (25 mg/kg/day) on days 0 and 3, followed by weekly injections for the remainder of the study. HMGB1 ASO administration significantly attenuated AngII-induced AAA formation in the absence of any changes in blood pressure.
conclusionsASO-driven HMGB1 inhibition resulted in a profound attenuation of AngII-induced AAA, highlighting its potential as a therapeutic target for AAAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.